ResMed (RMD) : Thompson Investment Management reduced its stake in ResMed by 2.9% during the most recent quarter end. The investment management company now holds a total of 56,523 shares of ResMed which is valued at $3,888,782 after selling 1,688 shares in ResMed , the firm said in a disclosure report filed with the SEC on Aug 1, 2016.ResMed makes up approximately 0.77% of Thompson Investment Management’s portfolio.
Other Hedge Funds, Including , California State Teachers Retirement System reduced its stake in RMD by selling 4,700 shares or 1.57% in the most recent quarter. The Hedge Fund company now holds 294,717 shares of RMD which is valued at $20,276,530. ResMed makes up approx 0.04% of California State Teachers Retirement System’s portfolio.Mai Capital Management reduced its stake in RMD by selling 375 shares or 2.6% in the most recent quarter. The Hedge Fund company now holds 14,050 shares of RMD which is valued at $925,614. ResMed makes up approx 0.07% of Mai Capital Management’s portfolio.
ResMed opened for trading at $68.6 and hit $69.45 on the upside on Thursday, eventually ending the session at $69.1, with a gain of 0.44% or 0.3 points. The heightened volatility saw the trading volume jump to 5,97,430 shares. Company has a market cap of $9,702 M.
On the company’s financial health, ResMed reported $0.74 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Jul 28, 2016. Analyst had a consensus of $0.75. The company had revenue of $518.60 million for the quarter, compared to analysts expectations of $514.35 million. The company’s revenue was up 14.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.68 EPS.
Investors should note that on Jul 28, 2016, ResMed announced a cash dividend of $0.3300. The company’s management has announced Aug 16, 2016 as the ex-dividend date and fixed the record date on Aug 18, 2016. The payable date has been fixed on Sep 22, 2016.
Many Wall Street Analysts have commented on ResMed. ResMed was Downgraded by Needham to ” Underperform” on Jun 27, 2016.
ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.